- Report
- October 2024
- 184 Pages
Global
From €3226EUR$3,545USD£2,766GBP
€3585EUR$3,939USD£3,073GBP
- Report
- July 2024
Global
From €4505EUR$4,950USD£3,862GBP
- Report
- April 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- March 2025
- 250 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- May 2023
- 391 Pages
Global
From €4368EUR$4,799USD£3,744GBP
- Report
- February 2020
- 360 Pages
Global
From €4459EUR$4,899USD£3,822GBP
- Report
- August 2022
- 150 Pages
Global
From €5415EUR$5,950USD£4,642GBP
- Report
- September 2023
- 140 Pages
Global
From €3275EUR$3,599USD£2,808GBP
- Report
- November 2023
- 175 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Report
- July 2023
- 113 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- December 2023
- 132 Pages
Global
From €865EUR$950USD£741GBP
The Antibody Fragment market within the context of Oncology Drugs is a rapidly growing field of biotechnology. Antibody Fragments are small pieces of antibodies that are used to target and treat cancer cells. They are designed to bind to specific antigens on the surface of cancer cells, allowing them to be targeted and destroyed. Antibody Fragments are also used to deliver drugs directly to cancer cells, increasing the effectiveness of the drug. This technology has been used to develop a variety of cancer treatments, including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates.
The Antibody Fragment market is expected to continue to grow as new treatments are developed and approved. This growth is driven by the increasing prevalence of cancer, as well as the need for more effective treatments.
Some companies in the Antibody Fragment market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more
